The international, prospective glanzmann thrombasthenia registry: Treatment modalities and outcomes of non-surgical bleeding episodes in patients with glanzmann thrombasthenia

Haematologica

Volumn 100, Issue 8, 2015, Pages 1031-1037

  Di Minno, Giovanni ^a   Zotz, Rainer B ^b   D’Oiron, Roseline ^c   Bindslev, Niels ^d   Di Minno, Matteo Nicola Dario ^a,e   Poon, Man Chiu ^f  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Centre for Blood Coagulation and Transfusion Medicine   (Germany)

^c BICÊTRE HOSPITAL   (France)

^d NOVO NORDISK A S   (Denmark)

^e CENTRO CARDIOLOGICO MONZINO   (Italy)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; BLEEDING; CHEMOTHERAPY; CHILD; CLINICAL TRIAL; DISEASE REGISTRY; DISEASE SEVERITY; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; GLANZMANN DISEASE; HEADACHE; HEART FAILURE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REBLEEDING; RESPIRATORY FAILURE; SCHOOL CHILD; SEPTICEMIA; SUBARACHNOID HEMORRHAGE; SURGICAL TECHNIQUE; THERAPY EFFECT; THROMBOCYTE TRANSFUSION; TREATMENT FAILURE; ADVERSE EFFECTS; COMPLICATION; DRUG ADMINISTRATION; HEMORRHAGE; MULTICENTER STUDY; REGISTER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIFIBRINOLYTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FACTOR VIIA; HEMORRHAGE; HUMANS; PLATELET TRANSFUSION; RECOMBINANT PROTEINS; REGISTRIES; SEVERITY OF ILLNESS INDEX; THROMBASTHENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84931330786     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.121475     Document Type: Article

References (23)

1. Caen JP, Castaldi PA, Leclerc JC, et al. Congenital bleeding disorders with long bleeding time and normal platelet count. 1. Glanzmann's thrombasthenia (report of fifteen patients). Am J Med. 1966;41(1):4-26
2. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75(7):1383-1395
3. Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br J Haematol. 1974;28(2):253-260
4. Nurden AT. Inherited abnormalities of platelets. Thromb Haemost. 1999;82(2):468-480
5. Reichert N, Seligsohn U, Ramot B. Clinical and genetic aspects of Glanzmann's thrombasthenia in Israel: report of 22 cases. Thromb Diath Haemorrh. 1975;34(3):806-820
6. Kannan M, Ahmad F, Yadav BK, Kumar R, Choudhry VP, Saxena R. Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia. J Thromb Haemost. 2009;7(11):1878-1885
7. Nurden AT, Nurden P. Inherited disorders of platelets: an update. Curr Opin Hematol. 2006;13(3):157-162
8. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118(23):5996-6005
9. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol. 2004;77(2):198-199
10. Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta. 2010;411(1-2):1-6
11. Di Minno G, Coppola A, Di Minno MN, Poon MC. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost. 2009;102(6):1157-1164
12. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3): 348-360
13. Martin I, Kriaa F, Proulle V, et al. Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol. 2002;119(4):991-997
14. Rebulla P. A mini-review on platelet refractoriness. Haematologica. 2005;90(2):247-253
15. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost. 1996;75(6):981-982
16. Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol. 2003;121(3):477-481
17. D'Oiron R, Menart C, Trzeciak MC, et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost. 2000;83(5):644-647
18. Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood. 1999;94 (11):3951-3953
19. Poon MC, D'Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost. 2004;2(7):1096-1103
20. NovoSeven® summary of product characteristics. http://www.ema.europa.eu/docs/ e n _GB/ d o c ume n t _ l i b r a r y/E PAR_ -_Product_Information/human/000074/WC5 00030873.pdf. Accessed July 23, 2014
21. Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol. 2006;43(1 Suppl 1):S33-S36
22. Santoro C, Rago A, Biondo F, et al. Prevalence of allo-immunization anti-HLA and anti-integrin alphaIIbbeta3 in Glanzmann thromboasthenia patients. Haemophilia. 2010;16(5):805-812
23. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4):692-694.